JP5611835B2 - 関連アプリケーションに相互参照する有効関連値を使用する対立遺伝子識別解析 - Google Patents
関連アプリケーションに相互参照する有効関連値を使用する対立遺伝子識別解析 Download PDFInfo
- Publication number
- JP5611835B2 JP5611835B2 JP2010540874A JP2010540874A JP5611835B2 JP 5611835 B2 JP5611835 B2 JP 5611835B2 JP 2010540874 A JP2010540874 A JP 2010540874A JP 2010540874 A JP2010540874 A JP 2010540874A JP 5611835 B2 JP5611835 B2 JP 5611835B2
- Authority
- JP
- Japan
- Prior art keywords
- signal
- amplification
- reaction
- medium
- efficiency
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108700028369 Alleles Proteins 0.000 title claims description 78
- 238000004458 analytical method Methods 0.000 title description 40
- 238000006243 chemical reaction Methods 0.000 claims description 187
- 230000003321 amplification Effects 0.000 claims description 160
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 160
- 150000007523 nucleic acids Chemical class 0.000 claims description 123
- 108020004707 nucleic acids Proteins 0.000 claims description 120
- 102000039446 nucleic acids Human genes 0.000 claims description 120
- 238000000034 method Methods 0.000 claims description 95
- 239000000523 sample Substances 0.000 claims description 46
- 238000005259 measurement Methods 0.000 claims description 43
- 230000009466 transformation Effects 0.000 claims description 35
- 230000004044 response Effects 0.000 claims description 23
- 239000003153 chemical reaction reagent Substances 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 230000006870 function Effects 0.000 claims description 11
- 238000000844 transformation Methods 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 238000003860 storage Methods 0.000 claims description 7
- 230000003287 optical effect Effects 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 description 34
- 238000003556 assay Methods 0.000 description 21
- 238000001514 detection method Methods 0.000 description 18
- 239000000975 dye Substances 0.000 description 18
- 238000003753 real-time PCR Methods 0.000 description 16
- 238000011160 research Methods 0.000 description 15
- 230000012010 growth Effects 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 101150005296 FCN1 gene Proteins 0.000 description 10
- 238000004364 calculation method Methods 0.000 description 10
- 239000013615 primer Substances 0.000 description 9
- 238000012408 PCR amplification Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 238000007834 ligase chain reaction Methods 0.000 description 7
- 239000002987 primer (paints) Substances 0.000 description 7
- 108010094028 Prothrombin Proteins 0.000 description 5
- 206010047249 Venous thrombosis Diseases 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 4
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 206010058279 Factor V Leiden mutation Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 102100027378 Prothrombin Human genes 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 229940039716 prothrombin Drugs 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000007844 allele-specific PCR Methods 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002795 fluorescence method Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000011901 isothermal amplification Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012092 media component Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 206010056867 Activated protein C resistance Diseases 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010061932 Factor VIIIa Proteins 0.000 description 1
- 108010074105 Factor Va Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000003366 endpoint assay Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010091897 factor V Leiden Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 201000002273 mucopolysaccharidosis II Diseases 0.000 description 1
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000001921 nucleic acid quantification Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011425 standardization method Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Evolutionary Biology (AREA)
- Wood Science & Technology (AREA)
- Evolutionary Computation (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioethics (AREA)
- Software Systems (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Signal Processing (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1753107P | 2007-12-28 | 2007-12-28 | |
| US61/017,531 | 2007-12-28 | ||
| US6074208P | 2008-06-11 | 2008-06-11 | |
| US61/060,742 | 2008-06-11 | ||
| PCT/US2008/088220 WO2009086415A1 (en) | 2007-12-28 | 2008-12-23 | Allelic discrimination analysis using an efficiency related value (efr) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014178854A Division JP5922204B2 (ja) | 2007-12-28 | 2014-09-03 | 関連アプリケーションに相互参照する有効関連値を使用する対立遺伝子識別解析 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011512787A JP2011512787A (ja) | 2011-04-28 |
| JP5611835B2 true JP5611835B2 (ja) | 2014-10-22 |
Family
ID=40824719
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010540874A Expired - Fee Related JP5611835B2 (ja) | 2007-12-28 | 2008-12-23 | 関連アプリケーションに相互参照する有効関連値を使用する対立遺伝子識別解析 |
| JP2014178854A Active JP5922204B2 (ja) | 2007-12-28 | 2014-09-03 | 関連アプリケーションに相互参照する有効関連値を使用する対立遺伝子識別解析 |
| JP2016080174A Pending JP2016154558A (ja) | 2007-12-28 | 2016-04-13 | 関連アプリケーションに相互参照する有効関連値を使用する対立遺伝子識別解析 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014178854A Active JP5922204B2 (ja) | 2007-12-28 | 2014-09-03 | 関連アプリケーションに相互参照する有効関連値を使用する対立遺伝子識別解析 |
| JP2016080174A Pending JP2016154558A (ja) | 2007-12-28 | 2016-04-13 | 関連アプリケーションに相互参照する有効関連値を使用する対立遺伝子識別解析 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US8093020B2 (https=) |
| EP (1) | EP2238262B1 (https=) |
| JP (3) | JP5611835B2 (https=) |
| CA (1) | CA2710195A1 (https=) |
| WO (1) | WO2009086415A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10127348B2 (en) | 2010-04-09 | 2018-11-13 | Life Technologies Corporation | Visualization tool for qPCR genotyping data |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2710195A1 (en) | 2007-12-28 | 2009-07-09 | Abbott Laboratories | Allelic discrimination analysis using an efficiency related value (efr) |
| CN109923613B (zh) * | 2016-06-02 | 2023-07-04 | Seegene株式会社 | 利用信号变化量数据集的样品内的目标分析物质检测方法 |
| US11031099B2 (en) * | 2016-11-09 | 2021-06-08 | Roche Molecular Systems, Inc. | Detection of sequence variants |
| CN109945911A (zh) * | 2017-12-15 | 2019-06-28 | 富泰华工业（深圳）有限公司 | 电子装置、拆机监测装置及方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02113305A (ja) | 1988-10-24 | 1990-04-25 | Fanuc Ltd | スプライン補間方法 |
| US7228237B2 (en) * | 2002-02-07 | 2007-06-05 | Applera Corporation | Automatic threshold setting and baseline determination for real-time PCR |
| EP1706836B1 (en) | 2003-12-06 | 2011-01-19 | Abbott Laboratories | Method and system for analyzing reactions using an information system |
| WO2006037207A1 (en) * | 2004-10-05 | 2006-04-13 | National Research Council Of Canada | Apparatus, process and methods for use with qantitative pcr |
| AU2005300646B2 (en) * | 2004-11-24 | 2007-10-25 | Bio-Rad Innovations | A method, an installation, and a computer program for estimating the initial size of a population of nucleic acids, in particular by PCR |
| US7991561B2 (en) | 2005-09-29 | 2011-08-02 | Roche Molecular Systems, Inc. | Ct determination by cluster analysis with variable cluster endpoint |
| US20070134652A1 (en) * | 2005-11-09 | 2007-06-14 | Primera Biosystems, Inc. | Multiplexed quantitative detection of pathogens |
| CA2710195A1 (en) | 2007-12-28 | 2009-07-09 | Abbott Laboratories | Allelic discrimination analysis using an efficiency related value (efr) |
-
2008
- 2008-12-23 CA CA2710195A patent/CA2710195A1/en not_active Abandoned
- 2008-12-23 WO PCT/US2008/088220 patent/WO2009086415A1/en not_active Ceased
- 2008-12-23 EP EP08866491.7A patent/EP2238262B1/en not_active Not-in-force
- 2008-12-23 JP JP2010540874A patent/JP5611835B2/ja not_active Expired - Fee Related
- 2008-12-23 US US12/343,233 patent/US8093020B2/en not_active Expired - Fee Related
-
2011
- 2011-12-08 US US13/315,133 patent/US20120156682A1/en not_active Abandoned
-
2013
- 2013-10-22 US US14/060,422 patent/US20140127793A1/en not_active Abandoned
-
2014
- 2014-09-03 JP JP2014178854A patent/JP5922204B2/ja active Active
-
2016
- 2016-04-13 JP JP2016080174A patent/JP2016154558A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10127348B2 (en) | 2010-04-09 | 2018-11-13 | Life Technologies Corporation | Visualization tool for qPCR genotyping data |
| US10629290B2 (en) | 2010-04-09 | 2020-04-21 | Life Technologies Corporation | Visualization tool for QPCR genotyping data |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2710195A1 (en) | 2009-07-09 |
| US8093020B2 (en) | 2012-01-10 |
| EP2238262A1 (en) | 2010-10-13 |
| JP5922204B2 (ja) | 2016-05-24 |
| JP2011512787A (ja) | 2011-04-28 |
| EP2238262B1 (en) | 2019-01-16 |
| US20090246777A1 (en) | 2009-10-01 |
| US20120156682A1 (en) | 2012-06-21 |
| WO2009086415A1 (en) | 2009-07-09 |
| JP2015027302A (ja) | 2015-02-12 |
| EP2238262A4 (en) | 2015-04-22 |
| US20140127793A1 (en) | 2014-05-08 |
| JP2016154558A (ja) | 2016-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Foy et al. | Emerging homogeneous DNA-based technologies in the clinical laboratory | |
| Germer et al. | High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR | |
| Germer et al. | Single-tube genotyping without oligonucleotide probes | |
| JP6190419B2 (ja) | 情報システムを用いて反応を解析する方法およびシステム | |
| US11781174B2 (en) | Calibration method, apparatus and computer program product | |
| JP5922204B2 (ja) | 関連アプリケーションに相互参照する有効関連値を使用する対立遺伝子識別解析 | |
| AU2006292252A2 (en) | Melting curve analysis with exponential background subtraction | |
| US12378602B2 (en) | Methods and kits for determining the efficiency of plasma separation from whole blood | |
| KR102699175B1 (ko) | 기울기 데이터 세트에 대한 s자 형태의 함수를 사용하여 샘플 내 타겟 분석물질을 검출하는 방법 | |
| Guo et al. | Rapid diagnosis of aneuploidy by high-resolution melting analysis of segmental duplications | |
| Guo et al. | Simultaneous Detection of Trisomies 13, 18, and 21 with Multiplex Ligation-Dependent Probe Amplification–Based Real-Time PCR | |
| Callegaro et al. | Algorithm for automatic genotype calling of single nucleotide polymorphisms using the full course of TaqMan real-time data | |
| Verri et al. | Two-step genetic screening of thrombophilia by pyrosequencing | |
| Yang et al. | A novel competitive fluorescent multiplex STR polymorphism assay for rapid, reliable and single‐tube screening of 22q11. 2 copy‐number aberrations | |
| Nagarajan et al. | Mutation Detection | |
| HK1220235B (en) | Calibration method, apparatus and computer program product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111216 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131029 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20140114 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140225 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20140225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140228 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20140303 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140305 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140623 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140710 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140804 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140903 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5611835 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |